NasdaqCM - Nasdaq Real Time Price USD

Sonnet BioTherapeutics Holdings, Inc. (SONN)

Compare
1.5800
+0.0300
+(1.94%)
At close: January 10 at 4:00:00 PM EST
1.5500
-0.03
(-1.90%)
After hours: January 10 at 6:38:13 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for SONN

Recent News: SONN

View More
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
GlobeNewswire 18 days ago
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire 24 days ago
Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire last month
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial
GlobeNewswire last month
Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action
GlobeNewswire last month
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
GlobeNewswire last month
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire 2 months ago
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
GlobeNewswire 2 months ago
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
GlobeNewswire 2 months ago
Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment

Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment
TipRanks 2 months ago
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
GlobeNewswire 3 months ago
View More

Related Tickers

PHIO Phio Pharmaceuticals Corp.
1.6900
0.00%
 
PSTV Plus Therapeutics, Inc.
1.1600
-3.33%
 
PALI Palisade Bio, Inc.
1.9100
-4.98%
 
NLSP NLS Pharmaceutics AG
2.3200
-3.73%
 
ADTX Aditxt, Inc.
0.1699
+1.01%
 
CYCC Cyclacel Pharmaceuticals, Inc.
0.4199
+1.21%
 
TCBP TC Biopharm (Holdings) Plc
0.4005
-1.11%
 
MBIO Mustang Bio, Inc.
0.2566
+15.38%
 
DRMA Dermata Therapeutics, Inc.
1.2000
-4.76%
 
VRPX Virpax Pharmaceuticals, Inc.
0.3650
-0.16%